Protagonist Therapeutics, Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Protagonist Therapeutics, Inc (PTGX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value of $501.30 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue · last filed 2026-02-25
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $501.30M.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $152.90M.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $60.00M.
- 2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $92.20M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value |
|---|---|
| 2025-12-31 | $501.30M 10-K · filed 2026-02-25 |
| 2024-12-31 | $152.90M 10-K · filed 2025-02-21 |
| 2023-12-31 | $60.00M 10-K · filed 2024-02-27 |
| 2023-06-30 | $92.20M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $63.30M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $6.90M 10-K · filed 2023-03-15 |
| 2022-09-30 | $2.30M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $1.70M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $46.00M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $102.70M 10-K · filed 2022-02-28 |
| 2021-09-30 | $27.60M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $173.10M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $66.30M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $40.00M 10-K · filed 2021-03-10 |
| 2020-09-30 | $38.80M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $32.80M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $2.20M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $2.40M 10-K · filed 2020-03-10 |
| 2019-09-30 | $10.70M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $12.30M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $14.10M 10-Q · filed 2019-05-08 |
| 2018-09-30 | $7.80M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $3.70M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $5.90M 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |